• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Christos S. Mantzoros, MD, ScD

Professor, Department of Medicine, Harvard Medical School

Chief, Endocrinology, VA Boston Healthcare System

Director Human Nutrition Unit, Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center

Contact Info

Christos Mantzoros
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA, 02215
Mailstop: FD 875
Phone: 617-667-8630
Fax: 617-667-8634
cmantzor@bidmc.harvard.edu

Assistant

Mary Brinkoetter
Beth Israel Deaconess Medical Center
Phone: 617-667-1656
Fax: 617-667-8634
mbrinkoe@bidmc.harvard.edu

DF/HCC Program Affiliation

Prostate Cancer

Lab Website

Christos S Mantzoros, Professor of Medicine HMS and Professor in Environmental Health HSPH

Research Abstract

My own active basic and clinical research program focuses on insulin resistance and the epidemiology and biology of adipose tissue secreted hormones. My basic research efforts utilize genomics-bioinformatics, animal physiology and molecular biology studies to elucidate the role of new molecules important in obesity and its complications, including diabetes and malignancies. My current translational / laboratory investigations focus mainly on the role of adipocyte secreted hormones, including leptin and adiponectin as well as their downstream effectors, on energy homeostasis and metabolic abnormalities including obesity, diabetes and its complications, including cardiovascular disease and cancer. Our work spans the entire spectrum from animal physiology and molecular biology, through observational, epidemiology studies, to physiology and pharmacokinetic interventional proof of concept clinical trials on new therapeutic agents important in the treatment of the above disorders in humans. Recent major contributions by my research group include the elucidation of the physiological role and potential diagnostic and therapeutic utility of leptin and adiponectin in human physiology and pathophysiology, especially in obesity and its complications, including malignancies. We have also studied the biology of insulin, IGFs, and insulin resistance in relation to diabetes and obesity-related malignancies. Our work has resulted in patents for diagnostic and therapeutic applications and has directly contributed to the development of new pharmaceuticals by major pharmaceutical companies. I have also co-founded Intekrin Metabolic Therapeutics which has developed a novel medication for diabetes which has successfully completed phase II clinical trials.

Publications

View All Publications